AUTHOR AND EDITOR INFORMATION

Section 1 of 9  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Follow-up
• Miscellaneous
• References

INTRODUCTION

Section 2 of 9  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Follow-up
• Miscellaneous
• References

Background

Amiodarone is a potent antiarrhythmic drug that is used to treat ventricular and supraventricular tachyarrhythmias. It is a benzofuran-derived, iodine-rich compound with some structural similarity to thyroxine (T4). Amiodarone contains approximately 37% iodine by weight. Each 200-mg tablet is estimated to contain about 75 mg of organic iodide, 8-17% of which is released as free iodide. Standard maintenance therapy with 200 mg amiodarone can provide more than 100 times the daily iodine requirement. It is highly lipid-soluble and is concentrated in the adipose tissue, muscle, liver, lung, and thyroid gland.

The elimination half-life of amiodarone is highly variable, ranging from 50-100 days; total body iodine stores remain increased for up to 9 months after discontinuation of the drug. Thyroid abnormalities have been noted in up to 14-18% of patients receiving long-term amiodarone therapy. However a recent meta-analysis suggested that with the lower doses of amiodarone (150-330 mg) incidence of thyroid dysfunction is 3.7%. The effects range from abnormal thyroid function test findings to overt thyroid dysfunction, which may be either amiodarone-induced thyrotoxicosis (AIT) or amiodarone-induced hypothyroidism (AIH). Both can develop in apparently normal thyroid glands or in glands with preexisting abnormalities.

Pathophysiology

Amiodarone causes a wide spectrum of effects on the thyroid.

• Amiodarone inhibits type 1 5'-deiodinase enzyme activity, thereby decreasing the peripheral conversion of T4 to triiodothyronine (T3) and reducing the clearance of both T4 and reverse T3 (rT3). Consequently, the serum levels of T4 and rT3 increase and the serum levels of T3 decrease by 20-25%.

• Amiodarone inhibits entry of T4 and T3 into the peripheral tissue. Serum T4 levels increase by an average of 40% above pretreatment levels after 1-4 months of treatment with amiodarone. This, in itself, does not constitute evidence of hyperthyroidism (thyrotoxicosis).

• Inhibition of type 2 5'-deiodinase enzyme activity in the pituitary due to feedback regulation is seen in the first 1-3 months and leads to an increase in thyroid-stimulating hormone (TSH) levels. This is not an indication for T4 replacement in these patients. Serum TSH levels return to normal in 2-3 months as T4 concentrations rise sufficiently to overcome the partial block in T3 production. The response of TSH to thyroid-releasing hormone (TRH) may be reduced.

• Amiodarone and its metabolites may have a direct cytotoxic effect on the thyroid follicular cells, which causes a destructive thyroiditis.

• Amiodarone and its metabolite desethylamiodarone can act as a competitive antagonist of T3 at the cardiac cellular level.

In summary, serum T4 levels rise by 20-40% during the first month of therapy and then gradually fall toward high normal. Serum T3 levels decrease by up to 30% within the first few weeks of therapy and remain slightly decreased or low normal. Serum rT3 levels increase by 20% soon afterward and remain increased. Serum thyrotropin (TSH) levels usually rise after the start of therapy but return to normal in 2-3 months.

Two forms of AIT have been described. Type 1 usually affects patients with latent or preexisting thyroid disorders and is more common in areas of low iodine intake. Type 1 is caused by iodine-induced excess thyroid hormone synthesis and release (Jod-Basedow phenomenon). Type 2 occurs in patients with a previously normal thyroid gland and is caused by a destructive thyroiditis that leads to the release of preformed thyroid hormones from the damaged thyroid follicular cells. However, mixed forms of AIT may occur in an abnormal thyroid gland, with features of destructive processes and iodine excess.

The most likely mechanisms of AIH are an enhanced susceptibility to the inhibitory effect of iodine on thyroid hormone synthesis and the inability of the thyroid gland to escape from the Wolff-Chaikoff effect after an iodine load in patients with preexisting Hashimoto thyroiditis. In addition, iodine-induced damage to the thyroid follicles may accelerate the natural trend of Hashimoto thyroiditis toward hypothyroidism. Patients without underlying thyroid abnormalities are postulated to have subtle defects in iodine organification that lead to decreased thyroid hormone synthesis, peripheral down regulation of thyroid hormone receptors, and subsequent hypothyroidism.

Frequency

United States

The prevalence of AIT in the United States is 3%; the prevalence of AIH is 22%. The relative prevalence of the 2 forms of AIT is unknown.

International

Some studies indicate that the incidence varies with the dietary iodine intake in the population. AIT occurs more frequently in geographical areas with low iodine intake, whereas AIH is more frequent in iodine-replete areas. However, in a Dutch study of persons with euthyroidism living in an area with moderately sufficient iodine intake, the incidence of AIT was twice that of AIH.

Mortality/Morbidity

Although amiodarone-associated thyroid dysfunction is usually a mild clinical condition, it can be severe, life threatening, and even lethal. Fatal cases of thyroid storm and myxedema coma have been reported despite various aggressive therapies.

Race

No well-described racial differences exist.

Sex

AIH is more frequent in females, with a female-to-male ratio of 1.5:1. AIT, however, is more frequent in males, with a male-to-female ratio of 3:1.

Age

The risk of AIH is higher in elderly persons, probably because of the higher prevalence of underlying thyroid abnormality.

CLINICAL

Section 3 of 9  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Follow-up
• Miscellaneous
• References

History

The clinical presentation of AIH is usually subtle, while that of AIT can be dramatic, with life-threatening cardiac manifestations without antecedent subclinical biochemical findings. Suspect AIT in a patient who was previously stable while receiving amiodarone but who starts to show signs of cardiac decompensation, tachyarrhythmias, or angina. However, patients may lack cardiac manifestations because of amiodarone's intrinsic effect on the heart, and other signs of hyperthyroidism such as weight loss and fatigue may predominate. Thyrotoxicosis can occur while a patient receives amiodarone and even several months after discontinuation of treatment. Hypothyroidism is rare after the first 18 months of therapy.

• Symptoms of AIT include the following:
  
  
  • Unexplained weight loss
  
  
  
  • Heat intolerance or increased perspiration
  
  
  
  • Profound muscle weakness
  
  
  
  • Unexplained fatigue
  
  
  
  • Emotional lability
  
  
  
  • Frequent stools
  
  
  
  • Oligomenorrhea
  
  
  
  • Anxiety, nervousness, or palpitations
     
• Symptoms of AIH include the following:
  
  
  • Fatigue
  
  
  
  • Lethargy
  
  
  
  • Cold intolerance
  
  
  
  • Mental sluggishness
  
  
  
  • Weakness
  
  
  
  • Constipation
  
  
  
  • Menorrhagia
  
  
  
  • Dry skin
     
• A family history of certain conditions can also be important. Consider the following:
  
  
  • Autoimmune disease
  
  
  
  • Thyroid disease
  
  
  
  • Medication history
  
  
  
  • Emigration from iodine-deficient areas

Physical

The physical signs of thyrotoxicosis or hypothyroidism induced by amiodarone therapy do not differ from those observed in states of thyroid excess or deficiency attributable to other causes.

• Signs of AIT include tremor, goiter, heart failure, sinus tachycardia, and atrial fibrillation.
• The presence of proptosis or multinodular or diffuse goiter usually indicates type 1 AIT. A small, often tender, goiter occasionally develops in patients with type 2 AIT.
• The clinical manifestations of AIH are similar to those of spontaneous hypothyroidism. Patients present with vague symptoms and signs such as fatigue, lethargy, cold intolerance, mental sluggishness, and dry skin. A goiter is found in 20% of patients with hypothyroidism who live in iodine-replete areas, but most of these goiters predate the start of amiodarone treatment. Myxedema coma has also been reported in a patient receiving long-term amiodarone therapy. In patients already receiving levothyroxine replacement therapy, the dose of levothyroxine may need to be increased to offset the amiodarone-induced inhibition of the T4-to-T3 conversion.

Causes

The risk of developing hypothyroidism or thyrotoxicosis is independent of the daily or cumulative dose of amiodarone. However, some small studies show the contrary. Autoimmune thyroid disease is the principal risk factor for the development of hypothyroidism. High dietary intake and a positive family history of thyroid disease may also be predisposing factors. Females with thyroid peroxidase or thyroglobulin antibodies have a relative risk of 13.5% for the development of hypothyroidism.

DIFFERENTIALS

Section 4 of 9  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Follow-up
• Miscellaneous
• References

WORKUP

Section 5 of 9  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Follow-up
• Miscellaneous
• References

Lab Studies

• Lab findings for AIH are similar to those for spontaneous hypothyroidism and include decreased levels of serum free T4 and increased levels of serum TSH. Serum thyroglobulin levels are often increased, probably because of TSH-enhanced thyroid stimulation.
• Lab findings for AIT are elevated levels of serum total and serum free T4 and T3 and undetectable levels of TSH. Low TSH levels and elevated free T4 levels are also commonly seen in the early phases of amiodarone therapy and in patients with severe nonthyroidal illness who have euthyroidism and are treated with amiodarone. Therefore, the measurement of free T3 levels may be helpful in differentiating the two because free T3 levels are increased in hyperthyroidism, while they are decreased in early phases of treatment with amiodarone. Serum rT3 levels are also markedly increased.
• Because amiodarone has no effect on the serum concentration of thyroid hormone-binding globulin, changes in the levels of free T4 and free T3 mirror those for total T4 and total T3.
• In the absence of hypothyroid symptoms, moderately elevated serum TSH levels with high normal or raised serum free T4 levels may reflect subclinical hypothyroidism. Close monitoring and repeat testing after 6 weeks is recommended.
• Serum sex hormone–binding globulin concentration is increased in patients with AIT but not in patients with hyperthyroxinemia and euthyroidism who are treated with amiodarone therapy. This assay is of limited importance, however, because of the numerous factors that affect the serum levels.
• Serum thyroglobulin levels are not diagnostic because they are usually higher in type 2 AIT but can be elevated in both types of AIT. Thyroglobulin levels can be increased in patients with goiters independent of the association with destructive thyroiditis.
• In some studies, serum interleukin 6 levels were lower in type 1 AIT and markedly elevated in type 2 AIT. The fact that interleukin 6 is also increased in patients with severe nonthyroidal illnesses limits the specificity of interleukin 6 determination.
• Thyroid autoantibodies are generally absent in type 2 AIT. The presence of autoantibodies supports the diagnosis of type 1 AIT. However, a test negative for autoantibodies does not rule out type 1 AIT.
• Urinary iodine excretion is not helpful in the initial assessment but may be useful long after the withdrawal of amiodarone to assess whether excess iodine levels are present.

Imaging Studies

• Although the above lab studies can confirm a diagnosis of thyrotoxicosis, further studies are necessary to recognize the correct type of AIT. This distinction is important when choosing treatment modalities.
• • A sonogram of the thyroid that shows abnormalities such as hypoechoic or nodular patterns or increased gland size is more indicative of type 1.

  • Radioactive iodine uptake studies are not helpful in the United States. Normal or elevated values found in radioactive iodine uptake studies suggest type 1 AIT, but this is rarely seen in the United States. The high levels of iodine result in serum levels that compete with the tracer used to perform the uptake test; thus, test results of both type 1 and type 2 usually have uptakes of less than 1%. Detectable 24-hour radioactive iodine uptake is seen in tests of most patients with AIH. This may be caused by excess stimulation of the thyroid by TSH.

• Color-flow Doppler ultrasonography visualizes the amount of blood flow within the thyroid. However, the accuracy of this tool is limited by the proficiency of the sonographer.
• • Pattern 0 (absent vascularity, gland destruction) is associated with type 2 AIT.

  • Patterns 1-3 (with vascularity) are associated with type 1 AIT.

• Most patients with AIH have been reported to have positive results on the perchlorate discharge test, indicating defects in intrathyroidal iodide organification. People with AIT have negative test results. These tests are rarely indicated or performed outside an academic setting.

Histologic Findings

A biopsy of the thyroid gland is unnecessary in most patients. The histological changes that occur with amiodarone administration have been studied in a research setting and include the following:

• Marked follicular disruption by diffuse fibrosis



• Epithelial atrophy



• Apoptosis



• Necrosis



• Markedly dilated endoplasmic reticulum



• Intraluminal aggregates of vacuolated cells



• Foci of nonspecific lymphocyte infiltration

TREATMENT

Section 6 of 9  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Follow-up
• Miscellaneous
• References

Medical Care

AIT presents a therapeutic challenge because data on optimal treatment are limited because of the lack of randomized, controlled trials.

• Differentiation of the two types of thyrotoxicosis is essential for determining the best management of the disease. However, one study in the United Kingdom found that the distinction between the two subtypes of AIT was not essential for treatment and found no difference in overall outcome between the two groups treated with thionamides alone. These results conflict with those of an Italian study, which found that type 2 AIT responds to steroids. This difference in results was attributed to the disparate levels of dietary iodine intake endemic to the two regions. The heterogeneity of patients with AIT (especially regarding iodine intake), the small number of patients studied in these trials, and the incomplete knowledge of the complex pathogenesis of the disease probably account for the contradictory results.
• The initial management of AIT involves deciding whether to discontinue amiodarone therapy. This depends on the patient's cardiac condition, the availability of alternate therapies, and the type of AIT present in the patient. Continuation of amiodarone treatment does not alter the basic approach to the medical management of thyrotoxicosis, but it reduces the chances of a successful outcome. In type 1 thyrotoxicosis, the persistently raised levels of intrathyroidal and circulating iodide reduce the effectiveness of treatment with antithyroid drugs.
• Mild AIT subsides spontaneously in up to 20% of cases upon discontinuation of amiodarone therapy. Many patients with type 2 AIT become euthyroid within 3-5 months after the discontinuation of amiodarone therapy. Occasionally, spontaneous remission occurs despite continued amiodarone use. Recurrences of type 2 AIT despite discontinuation of amiodarone have also been documented. Spontaneous remissions of type 1 AIT have not been documented.
  
  
  • Even if amiodarone therapy is stopped, thyrotoxicosis persists for up to 8 months because of the drug's long half-life. Discontinuation of the drug has no immediate benefit.
  • No randomized, controlled trials exist that determine the effect of stopping amiodarone therapy in patients with AIT. This decision is made in consultation with the cardiologist. Amiodarone therapy is usually continued unless it is ineffective in treating the arrhythmia or toxicity in other organs is evident. Moreover, stopping amiodarone therapy may exacerbate symptoms of thyrotoxicosis, as it blocks T4-to-T3 conversion and beta-adrenergic receptors. On the other hand, severe thyrotoxicosis may be incompatible with continuation of amiodarone treatment unless a thyroidectomy is performed.
• Type 1 thyrotoxicosis
  
  
  • Type 1 thyrotoxicosis is treated with high doses of thionamides (eg, methimazole [40-60 mg/d] or propylthiouracil [600-800 mg/d]) to block thyroid hormone synthesis. Thionamides block hormone synthesis by blocking both iodine organification and the coupling of iodotyrosines. Because of the large number of preformed thyroid hormones, the blocking effect is delayed and may take as long as 2-4 months.
  • Adding potassium perchlorate may block iodide uptake by the thyroid and deplete intrathyroidal iodine stores. Thus, perchlorate prevents further synthesis of thyroid hormones and improves the therapeutic efficacy of thionamides. Some studies have found good results with adding potassium perchlorate, and some have not. Potassium perchlorate is not US Food and Drug Administration (FDA) approved for the treatment of thyrotoxicosis and has to be ordered directly from Mallinckrodt, Inc. Because potassium perchlorate is a drug that potentially causes aplastic anemia, limit it to patients whose condition cannot be controlled by methimazole alone. The dose of perchlorate is 600-1000 mg/d. Do not administer potassium perchlorate for longer than 30 days because of serious adverse effects such as aplastic anemia, nephrotic syndrome, and agranulocytosis. Perform careful hematological examinations regularly during administration of potassium perchlorate.
  • Because all antithyroid drugs can cause bone marrow suppression, instruct patients to watch for signs such as fever, sore throat, or oral ulcers. The administration of thionamides is usually tapered to a low maintenance dose and is continued until amiodarone therapy is started. If amiodarone therapy is subsequently discontinued, the thionamides are continued until urine iodine levels return to normal (usually in 6-18 mo).
• Type 2 thyrotoxicosis
  
  
  • Type 2 thyrotoxicosis is treated with a relatively long course of glucocorticoids. In addition to their membrane-stabilizing and anti-inflammatory effects, glucocorticoids reduce conversion of T4 to T3 by inhibiting type 1 5'-deiodinase activity. If the patient does not have any symptoms of thyrotoxicosis or a life-threatening arrhythmia that requires amiodarone therapy, the initial treatment would be discontinuation of amiodarone and continued monitoring of thyroid function.
  • Administer prednisone at 30-40 mg/d and taper over a couple of months until free T4 levels are within the reference range. The symptoms may biochemically and clinically improve within one week following the start of therapy. Consider osteoporosis prophylaxis in patients at high risk for osteoporosis or in whom steroids are continued for more than 3 months.
• When the mechanism of hyperthyroidism is uncertain, a combination of glucocorticoids and thionamides is used as initial therapy. A rapid response suggests type 2 AIT; thionamides can be tapered. A poor initial response suggests type 1 AIT; the steroids can be tapered and the patient can be treated for type 1 AIT. 
• Regardless of the chosen medical regimen, the toxic state invariably takes several weeks to control because of the large stores of preformed intrathyroidal hormones.
• If thyrotoxicosis is exacerbated after initial control, it is usually treated with steroids. In type 1 AIT, this exacerbation may be due to mixed forms, which respond to the addition of steroids. In type 2 AIT, relapse can occur after discontinuation of corticosteroid treatment, and steroid treatment may need to be restarted.
• If amiodarone therapy is discontinued, beta-blockers and iopanoic acid may be added to ameliorate hyperthyroid symptoms exacerbated by amiodarone withdrawal.
• Radioactive iodine can be used in the rare patients with high radioactive iodine uptake; otherwise, the iodine of amiodarone inhibits uptake by the gland. Moreover, radioactive iodine often initially exacerbates the hyperthyroid state by releasing preformed hormone that is stored in the thyroid.
• Plasmapheresis is an expensive treatment that has transient benefits and is usually followed by an exacerbation of AIT. The efficacy of lithium and iopanoic acid for the management of AIT has not been confirmed in large, randomized, controlled trials.
• Thyroid ablation is a valid management option for type 1 AIT once euthyroidism has been restored, especially if amiodarone therapy must be restarted. Type 2 AIT requires strict follow-up because of possible progression to hypothyroidism, either spontaneously or after iodine re-exposure.
• Hypothyroidism in patients with no preexisting thyroid disease often resolves after discontinuation of amiodarone therapy. However, hypothyroidism may persist after discontinuation of treatment in patients with underlying chronic autoimmune thyroiditis and high titers of anti-TPO antibodies. In this case, the patient may require permanent T4 replacement therapy. Amiodarone therapy is usually continued while T4 is used to normalize the TSH level. In view of the often-severe underlying cardiac disease, consider maintaining the serum TSH concentration in the upper half of the reference range. Levothyroxine is the drug of choice because it is not associated with the spikes in serum thyroid hormone concentrations observed in patients given L-T3, which also requires multiple daily doses. However, if amiodarone therapy is continued, larger doses of T4 are required to offset the inhibitory effects of amiodarone on the conversion of T4 to T3.

Surgical Care

Total or near-total thyroidectomy is performed in cases of AIT that fail to respond to combination therapy with thionamides, perchlorate, and corticosteroids. Thyroidectomy is also performed in patients who need amiodarone therapy but whose resulting hyperthyroidism does not respond to medical treatment and for immediate control of a thyrotoxic state (eg, during thyroid storm) or in those with intractable arrhythmias. Treat the resulting hypothyroidism with thyroid hormone replacement. Despite the minimally elevated risk due to underlying heart disease, surgery is reasonably safe in these patients and can even be performed with local anesthesia.

Consultations

Consultation with an endocrinologist is recommended. Consult with a cardiologist to decide whether or not to continue amiodarone therapy.

Diet

No dietary restrictions apply, but excess amounts of iodide found in some expectorants, contrast dyes, seaweed tablets, and health food supplements should be avoided.

Activity

Restriction of activity is prudent in elderly persons or in patients with severe thyrotoxicosis with cardiovascular symptoms. Otherwise, no activity restrictions are necessary.

FOLLOW-UP

Section 7 of 9  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Follow-up
• Miscellaneous
• References

Further Outpatient Care

Prolonged monitoring of thyroid function tests is necessary in patients with AIT, even if they become euthyroid, as they may become hypothyroid. Recurrences are common in type 2 AIT.

Transfer

In cases of severe AIT or myxedema coma, consider a transfer to a specialized facility if an endocrinologist, intensivist, or cardiologist is not available to help with inpatient treatment.

Deterrence/Prevention

Test baseline thyroid function in all patients starting amiodarone therapy to exclude underlying gland dysfunction that may predispose them to thyroid abnormalities after therapy begins. The serum levels of TSH, free T4, and free T3 may be reassessed after 3 months of amiodarone therapy. In patients with euthyroidism, thyroid function results may be used as reference for future comparisons. Periodically monitor serum TSH levels and other thyroid indices if TSH levels are abnormal or clinical suspicion of thyroid dysfunction exists. The threshold for performing thyroid function tests should be low in patients who are taking amiodarone or who have in the past, as type 2 AIT has an abrupt onset. Continue to measure thyroid function for at least a year after amiodarone therapy is discontinued.

Complications

• Hyperthyroidism, thyroid storm



• Hypothyroidism, myxedema coma



• Aplastic anemia secondary to perchlorate use



• Agranulocytosis or hepatitis secondary to thionamides

Prognosis

• The prognosis for AIT may be very poor even though a wide range of antithyroid therapy is available. This prognosis emphasizes the need for careful monitoring of patients receiving amiodarone treatment.

• The long-term prognosis for AIH is usually good.

Patient Education

• Instruct patients about the adverse effects of amiodarone therapy. Give them a list of potential symptom manifestations. Because the development of thyrotoxicosis is sudden and explosive, instruct patients to watch for symptoms and to seek treatment promptly.

• Patients should also be aware of the potential side effects of antithyroid medications. Instruct patients to watch for signs such as fever, sore throat, jaundice, or oral ulcers.

MISCELLANEOUS

Section 8 of 9  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Follow-up
• Miscellaneous
• References

Medical/Legal Pitfalls

• Failure or delay in recognizing and treating AIT or AIH could result in patient mortality and litigation.

Special Concerns

• The use of amiodarone or any dose or duration during pregnancy may lead to transient neonatal hypothyroidism. Exposure to amiodarone may also be associated with neurodevelopmental abnormalities, even in the absence of thyroid disease. Completely normal development has also been reported.
• Neonates are very sensitive to iodine-induced hypothyroidism. Because amiodarone is secreted in breast milk, breastfeeding is not absolutely contraindicated but carries the risk of exposure. Therefore, thyroid function should be carefully monitored to exclude the possible occurrence of AIH.

REFERENCES

Section 9 of 9

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Follow-up
• Miscellaneous
• References

• Amico JA, Richardson V, Alpert B, Klein I. Clinical and chemical assessment of thyroid function during therapy with amiodarone. Arch Intern Med. Mar 1984;144(3):487-90. [Medline].
• Bartalena L, Brogioni S, Grasso L, et al. Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study. J Clin Endocrinol Metab. Aug 1996;81(8):2930-3. [Medline].
• Bartalena L, Grasso L, Brogioni S, et al. Serum interleukin-6 in amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab. Feb 1994;78(2):423-7. [Medline].
• Bogazzi F, Bartalena L, Brogioni S, et al. Color flow Doppler sonography rapidly differentiates type I and type II amiodarone-induced thyrotoxicosis. Thyroid. Aug 1997;7(4):541-5. [Medline].
• Bogazzi F, Bartalena L, Gasperi M, et al. The various effects of amiodarone on thyroid function. Thyroid. May 2001;11(5):511-9. [Medline].
• Claxton S, Sinha SN, Donovan S, et al. Refractory amiodarone-associated thyrotoxicosis: an indication for thyroidectomy. Aust N Z J Surg. Mar 2000;70(3):174-8. [Medline].
• Daniels GH. Amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab. Jan 2001;86(1):3-8. [Medline].
• Eaton SE, Euinton HA, Newman CM, et al. Clinical experience of amiodarone-induced thyrotoxicosis over a 3-year period: role of colour-flow Doppler sonography. Clin Endocrinol (Oxf). Jan 2002;56(1):33-8. [Medline].
• Figge J, Dluhy RG. Amiodarone-induced elevation of thyroid stimulating hormone in patients receiving levothyroxine for primary hypothyroidism. Ann Intern Med. Oct 1 1990;113(7):553-5. [Medline].
• Hamoir E, Meurisse M, Defechereux T, et al. Surgical management of amiodarone-associated thyrotoxicosis: too risky or too effective?. World J Surg. Jun 1998;22(6):537-42; discussion 542-3. [Medline].
• Harjai KJ, Licata AA. Effects of amiodarone on thyroid function. Ann Intern Med. Jan 1 1997;126(1):63-73. [Medline].
• Hermida JS, Jarry G, Tcheng E, Moullart V, Arlot S, Rey JL. Radioiodine ablation of the thyroid to allow the reintroduction of amiodarone treatment in patients with a prior history of amiodarone-induced thyrotoxicosis. Am J Med. Mar 1 2004;116(5):345-8. [Medline].
• Martino E, Aghini-Lombardi F, Mariotti S, et al. Amiodarone iodine-induced hypothyroidism: risk factors and follow-up in 28 cases. Clin Endocrinol (Oxf). Feb 1987;26(2):227-37. [Medline].
• Martino E, Aghini-Lombardi F, Mariotti S, et al. Treatment of amiodarone associated thyrotoxicosis by simultaneous administration of potassium perchlorate and methimazole. J Endocrinol Invest. Jun 1986;9(3):201-7. [Medline].
• Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocr Rev. Apr 2001;22(2):240-54. [Medline].
• Martino E, Safran M, Aghini-Lombardi F, et al. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann Intern Med. Jul 1984;101(1):28-34. [Medline].
• Newman CM, Price A, Davies DW, et al. Amiodarone and the thyroid: a practical guide to the management of thyroid dysfunction induced by amiodarone therapy. Heart. Feb 1998;79(2):121-7. [Medline].
• Osman F, Franklyn JA, Sheppard MC, Gammage MD. Successful treatment of amiodarone-induced thyrotoxicosis. Circulation. Mar 19 2002;105(11):1275-7. [Medline].
• Roti E, Minelli R, Gardini E, et al. Thyrotoxicosis followed by hypothyroidism in patients treated with amiodarone. A possible consequence of a destructive process in the thyroid. Arch Intern Med. Apr 12 1993;153(7):886-92. [Medline].
• Smyrk TC, Goellner JR, Brennan MD, Carney JA. Pathology of the thyroid in amiodarone-associated thyrotoxicosis. Am J Surg Pathol. Mar 1987;11(3):197-204. [Medline].
• Trip MD, Wiersinga W, Plomp TA. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med. Nov 1991;91(5):507-11. [Medline].
• Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol. Sep 1997;30(3):791-8. [Medline].
• Williams M, Lo Gerfo P. Thyroidectomy using local anesthesia in critically ill patients with amiodarone-induced thyrotoxicosis: a review and description of the technique. Thyroid. Jun 2002;12(6):523-5. [Medline].
• Wolff J. Perchlorate and the thyroid gland. Pharmacol Rev. Mar 1998;50(1):89-105. [Medline].

Article Last Updated: Jul 24, 2007